reports
Median Technologies: 1 director
A director at Median Technologies bought 60,241 shares at 1.660EUR and the significance rating of the trade was 60/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cl...
- Maria Vara
Median Technologies: EUR23.5m capital raise extends runway into Q4 202...
Median Technologies successfully secured a capital raise via ABSA of EUR23.5m in total gross proceeds, priced at EUR1.66 (at ~18% discount to 20-day VWAP). The offering was oversubscribed, surpassing the initial EUR22m target, with 64% backed by existing shareholders, 2% by a public offering in Fra
- Maria Vara
Median Technologies: Launch of EUR22m capital increase to unlock EIB f...
Median Technologies has launched a EUR22m capital increase via a public offering of shares with warrants (ABSA), priced at EUR1.66 (at ~18% discount to 20-day VWAP), with 78% of the deal already secured via existing and new investors. The raise aimed to i) meet the drawing conditions of the Tranche
- Maria Vara
Median Technologies: EIB loan signed, tied to equity raise and debt re...
Friday post-market, Median announced the final sign of the EIB loan agreement of EUR37.5m, which has been structured in three tranches (EUR19m, EUR8.5m, EUR10m) and with several key conditions being set to access the first one. These include i) a capital increase of at least EUR16m (including issua
- Maria Vara
Median Technologies: CE mark filing keep eyonis on track, US launch be...
Yesterday post-market, Median announced that it has submitted the Class IIb CE marking filing for eyonis LCS, just a month after the FDA 510(k) submission, precisely sticking to the company's timeline guidance. Our confidence in a positive outcome remains high, as both submissions are underpinned b
- Maria Vara
Median Technologies: eyonis LCS heads for FDA nod in Q3 2025
This morning, Median announced that it has submitted a 510(k) FDA filing for eyonis LCS, remaining on track with prior guidance and with a plausible clearance expected in Q3 2025. We are confident in a positive outcome, as the submission is underpinned by two pivotal studies—REALITY and RELIVE—whic
- Maria Vara
Median Technologies: FY24 wrap-up signals cost discipline, outlook rei...
Median Technologies released its audited FY 2024 results, which contain no surprises versus the unaudited data already disclosed in prior updates (see Q4 2024 and Q1 2025 notes). Revenue for the year came in at EUR22.9m (+3.3% YoY), fully driven by iCRO services, and the order backlog stood at EUR7
- Maria Vara
Median Technologies: eyonis on track, backlog at record high
Median Technologies started 2025 with a continued positive momentum on iCRO revenues, which grew 11% YoY to EUR6m, backed by a record EUR74.8m order backlog (+5.4% QoQ) driven by new wins from a Top 3 pharma client. Q1 was a pivotal quarter on the clinical side, with the pivotal RELIVE study for ey
- Maria Vara
Median technologies: Full RELIVE results cement eyonis case, to launch...
Yesterday post-market, Median Technologies released the full results from its pivotal RELIVE study, confirming that eyonis LCS, its AI-powered SaMD for lung cancer screening, met all secondary endpoints in addition to the previously announced primary endpoint (p = 0.027). The final data reinforces
Median Technologies répond aux conditions d’éligibilité du dispositif ...
SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)-- Regulatory News: Median Technologies (FR0011049824, ALMDT) confirme aujourd’hui son éligibilité au dispositif PEA-PME conformément aux dispositions des articles L. 221-32-2 et D. 221-113-5 et suivant du Code monétaire et financier précisant les conditions d'appréciation des critères d'éligibilité, à savoir : Moins de 5 000 salariés, Un chiffre d'affaires annuel inférieur à 1,5 milliard d'euros ou un total de bilan inférieur à 2 milliards d'euros. Les actions Median Technologies continuent en conséquence d'être intégrées au sein des comptes PEA...
Median Technologies annonce la mise à disposition des documents prépar...
SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)-- Regulatory News: Les actionnaires de la Société Median Technologies (FR0011049824, ALMDT, éligible au plan PEA/PME, “Median” ou “La Société”) sont invités à participer à l’Assemblée générale extraordinaire qui se tiendra jeudi 20 mars 2025, à 10h15 CET, dans les locaux du Cabinet PDGB au 174 avenue Victor Hugo à Paris (75116). Toutes les informations utiles relatives à cette Assemblée sont régulièrement mises à jour sur le site de la société Median Technologies. Les actionnaires peuvent exercer leur droit de vote préalablement à la tenue de l’A...
Median Technologies fera une présentation à la 45ème conférence annuel...
SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)-- Regulatory News: Median Technologies (FR0011049824, ALMDT, éligible PEA/PME, « Median » ou « La Société »), développeur d'eyonis™, une suite de logiciels dispositifs médicaux basés sur l'intelligence artificielle (IA) pour le diagnostic précoce des cancers, et un leader mondial de la fourniture d'analyses d’images par IA et de services centraux d'imagerie pour les essais cliniques en oncologie de l’industrie biopharmaceutique, annonce sa participation à la 45ème conférence annuelle Health Care de TD Cowen, du 3 au 5 mars 2025 au Boston Marriott Cop...
Median Technologies to Present at TD Cowen’s 45th Annual Health Care C...
SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)-- Regulatory News: Median Technologies (FR0011049824, ALMDT, PEA/SME eligible, “Median” or “The Company”), a leading developer of eyonis™, a suite of artificial intelligence (AI) powered Software as a Medical Device (SaMD) for early cancer diagnostics, and a globally leading provider of AI-powered imaging analyses and central imaging services for oncology drug developers, announced today that it will participate in TD Cowen’s 45th Annual Health Care Conference, taking place March 3-5 in Boston, MA. Fredrik Brag, Median’s CEO and Founder, will prese...
Median Technologies présentera son logiciel dispositif médical basé su...
SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)-- Regulatory News: Median Technologies (FR0011049824, ALMDT, éligible PEA/PME, « Median » ou « La Société ») développeur d'eyonis™, une suite de logiciels dispositifs médicaux basés sur l'intelligence artificielle (IA) pour le diagnostic précoce des cancers, et un leader mondial de la fourniture d'analyses d’images par IA et de services centraux d'imagerie pour les essais cliniques en oncologie de l’industrie biopharmaceutique, annonce aujourd’hui sa participation à l’ECR (European Congress of Radiology), qui se tiendra à Vienne, Autriche du 26 févri...
Median Technologies to Showcase Its Artificial Intelligence Software a...
SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)-- Regulatory News: Median Technologies (FR0011049824, ALMDT, PEA/SME eligible, “Median” or “The Company”), a leading developer of eyonis™, a suite of artificial intelligence (AI) powered Software as a Medical Device (SaMD) for early cancer diagnostics, and a globally leading provider of AI-powered imaging analyses and central imaging services for oncology drug developers, today announced that it will attend the European Congress of Radiology (ECR) 2025 in Vienna, from Feb. 26 to March 2. The Median eyonis™ team will welcome interested parties at Bo...
Median Technologies : Déclaration du nombre total de droits de vote et...
SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)-- Regulatory News: Median Technologies (Paris:ALMDT) : Nombre d'actions composant le capital 18 631 386 Nombre réel de droits de vote* (déduction faite des actions auto-détenues**) 18 567 201 Nombre théorique des droits de vote* (y compris actions auto-détenues**) 18 608 186 (*) Les actions de préférence de catégorie E sont sans droits de vote (**) En application de l’article 223-11 du Règlement Général de l’Autorité des Marchés Financiers A propos de Median Technologies : Pionnière dans les logiciels di...
Median Technologies fait un point sur les tirages du financement en fo...
SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)-- Regulatory News: Median Technologies (FR0011049824, ALMDT, éligible PEA/PME, « Median » ou « La Société ») développeur d'eyonis™, une suite de logiciels dispositifs médicaux basés sur l'intelligence artificielle (IA) pour le diagnostic précoce des cancers, et un des leaders mondiaux de la fourniture d'analyses d’images par IA et de services d'imagerie pour les essais cliniques en oncologie de l’industrie biopharmaceutique, a annoncé avoir signé le 23 janvier avec la société Iris un financement sous forme d’obligations remboursables en actions pour ...
- Maria Vara
Median Technologies: market reaction undervalues eyonis potential
On Monday, Median Technologies' stock surged 16.3% after announcing that RELIVE met its primary endpoint. However, the stock plummeted yesterday following a webinar hosted by the CEO, as investors viewed the performance difference between groups as modest, with an AUC difference of 0.016, implying
- Maria Vara
Median Technologies: RELIVE hits endpoint, paving the way for eyonis c...
This morning, Median Technologies released a key catalyst paving the commercial path for eyonis LCS: the topline results of the second pivotal study, RELIVE, which successfully met the primary endpoint with statistical significance (p = 0.027). In other words, the trial demonstrated that radiologis
Median Technologies : eyonis™ LCS atteint son critère d’évaluation pri...
SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)-- Regulatory News: Median Technologies (Paris:ALMDT) : Fredrik Brag, Directeur Général de Median Technologies, tiendra deux webconférences le 4 février « Nouveaux horizons dans la lutte contre le cancer du poumon : résultats de l’étude RELIVE d’eyonis™ LCS et prochaines étapes vers les autorisations de mise sur le marché » 4 février 2025 – 14h00 CET (webconférence en français) : 4 février 2025 – 16h00 CET / 10h00 EDT (webcast en anglais) : Les enregistrements des webconférences seront disponibles sur le après les sessions en direct Me...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.